West Pharmaceutical Services Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $872.3M | $844.9M | $805.0M | $804.6M | $766.5M | $698.0M | $748.8M | $746.9M |
| Cost of Revenue | $543.1M | $548.5M | $501.1M | $510.3M | $492.6M | $466.1M | $475.2M | $482.2M |
| Gross Profit | $329.2M | $296.4M | $303.9M | $294.3M | $273.9M | $231.9M | $273.6M | $264.7M |
| Gross Margin | 37.7% | 35.1% | 37.8% | 36.6% | 35.7% | 33.2% | 36.5% | 35.4% |
| Operating Expenses | ||||||||
| Research & Development | $19.7M | $15.8M | $21.8M | $17.1M | $19.1M | $16.3M | $18.5M | $15.5M |
| SG&A Expense | $117.6M | $99.5M | $107.0M | $102.7M | $95.9M | $88.0M | $85.3M | $83.5M |
| Operating Income | $179.1M | $177.1M | $156.6M | $167.6M | $153.7M | $107.0M | $159.6M | $161.3M |
| Operating Margin | 20.5% | 21.0% | 19.5% | 20.8% | 20.1% | 15.3% | 21.3% | 21.6% |
| Interest Expense | — | — | — | — | — | — | — | $700.0K |
| Pretax Income | $180.1M | $180.1M | $161.5M | $171.9M | $157.0M | $110.5M | $164.9M | $164.5M |
| Income Tax Expense | $32.2M | $44.7M | $33.3M | $34.0M | $30.2M | $24.1M | $36.8M | $32.4M |
| Net Income | $154.0M | $138.8M | $132.1M | $140.0M | $131.8M | $89.8M | $130.1M | $136.0M |
| Net Margin | 17.7% | 16.4% | 16.4% | 17.4% | 17.2% | 12.9% | 17.4% | 18.2% |
| EPS (Basic) | $2.17 | $1.93 | $1.83 | $1.94 | $1.82 | $1.24 | $1.79 | $1.87 |
| EPS (Diluted) | $2.15 | $1.92 | $1.82 | $1.92 | $1.82 | $1.23 | $1.78 | $1.85 |
| Shares Outstanding (Basic) | 70.8M | 72.0M | 72.3M | 72.2M | 72.2M | 72.5M | 73.0M | 72.8M |
| Shares Outstanding (Diluted) | 71.3M | 72.4M | 72.7M | 72.6M | 72.5M | 73.0M | 73.7M | 73.4M |
| Dividends Per Share | — | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 | — | — |